{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:35:03Z","timestamp":1787240103040,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92169211"],"award-info":[{"award-number":["92169211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Meplazumab, a humanized CD147 antibody, has shown favourable safety and efficacy in our previous clinical studies. In DEFLECT (NCT04586153), 167 patients with severe COVID-19 were enroled and randomized to receive three dosages of meplazumab and a placebo. Meplazumab at 0.12\u2009mg\/kg, compared to the placebo group, showed clinical benefits in significantly reducing mortality by 83.6% (2.4% vs. 14.6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0150), increasing the proportion of patients alive and discharged without supplemental oxygen (82.9% vs. 70.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0337) and increasing the proportion of patients who achieved sustained clinical improvement (41.5% vs. 31.7%). The response rate in the 0.2\u2009mg\/kg group was relatively increased by 16.0% compared with the placebo group (53.7% vs. 46.3%). Meplazumab also reduced the viral loads and multiple cytokine levels. Compare with the placebo group, the 0.3\u2009mg\/kg significantly increased the virus negative rate by 40.6% (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0363) and reduced IL-8 level (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0460); the 0.2\u2009mg\/kg increased the negative conversion rate by 36.9%, and reduced IL-4 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0365) and IL-8 levels (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0484). In this study, the adverse events occurred at a comparable rate across the four groups, with no unexpected safety findings observed. In conclusion, meplazumab promoted COVID-19 convalescence and reduced mortality, viral load, and cytokine levels in severe COVID-19 population with good safety profile.\n                  <\/jats:p>","DOI":"10.1038\/s41392-023-01323-9","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:03:45Z","timestamp":1675062225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2\/3, randomized, third-party double-blind clinical trial"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4690-4622","authenticated-orcid":false,"given":"Huijie","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Xuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Jie","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8913-7115","authenticated-orcid":false,"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Hua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Lin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Feng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1610-8748","authenticated-orcid":false,"given":"Nosheen","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iffat","family":"Khanum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Marcel Berdun","family":"Stadnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengi","family":"Itinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C\u00e2ndida Carvalho","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Dusilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Rivabem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adilson Joaquim Westheimer","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzara Souto","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladmir Faustino","family":"Saporito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio Jos\u00e9 Concilio","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Abraham","family":"Simon-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"1323_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10238-020-00671-y","volume":"21","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou, M. et al. Emerging treatment strategies for COVID-19 infection. Clin. Exp. Med. 21, 167\u2013179 (2021).","journal-title":"Clin. Exp. Med."},{"key":"1323_CR2","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int (2022)."},{"key":"1323_CR3","unstructured":"FDA. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19 (2020)."},{"key":"1323_CR4","unstructured":"Eli Lilly and Company. Lilly\u2019s Bebtelovimab Receives Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-bebtelovimab-receives-emergency-use-authorization (2022)."},{"key":"1323_CR5","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.drup.2021.100794","volume":"59","author":"S Dro\u017cd\u017cal","year":"2021","unstructured":"Dro\u017cd\u017cal, S. et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat 59, 100794 (2021).","journal-title":"Drug Resist Updat"},{"key":"1323_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","volume":"399","author":"RECOVERY Collaborative Group.","year":"2022","unstructured":"RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 665\u2013676 (2022).","journal-title":"Lancet"},{"key":"1323_CR7","unstructured":"Zhihao, Z. Antibody Combination Therapy Approved to Treat COVID-19. http:\/\/english.nmpa.gov.cn\/2021-12\/10\/c_690037.htm (2021)."},{"key":"1323_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2021","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2021).","journal-title":"Nature"},{"key":"1323_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-020-00426-x","volume":"5","author":"K Wang","year":"2020","unstructured":"Wang, K. et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target Ther. 5, 283 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"1323_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13578-022-00822-6","volume":"12","author":"S Badeti","year":"2022","unstructured":"Badeti, S. et al. Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. Cell Biosci. 12, 88 (2022).","journal-title":"Cell Biosci."},{"key":"1323_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-021-00760-8","volume":"6","author":"J Geng","year":"2021","unstructured":"Geng, J. et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal Transduct. Target Ther. 6, 347 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"1323_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","volume":"21","author":"J Tian","year":"2020","unstructured":"Tian, J. et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 21, 893\u2013903 (2020).","journal-title":"Lancet Oncol."},{"key":"1323_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41392-022-01230-5","volume":"7","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis. Signal Transduct. Target Ther. 7, 382 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"1323_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41392-021-00603-6","volume":"6","author":"H Bian","year":"2021","unstructured":"Bian, H. et al. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial. Signal Transduct. Target Ther. 6, 194 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"1323_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19057-5","volume":"11","author":"J Fajnzylber","year":"2020","unstructured":"Fajnzylber, J. et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 11, 5493 (2020).","journal-title":"Nat. Commun."},{"key":"1323_CR16","first-page":"9926249","volume":"2021","author":"W Chen","year":"2021","unstructured":"Chen, W. et al. Correlation analysis between the viral load and the progression of COVID-19. Comput Math. Methods Med. 2021, 9926249 (2021).","journal-title":"Comput Math. Methods Med."},{"key":"1323_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(21)02346-1","volume":"399","author":"RW Peeling","year":"2022","unstructured":"Peeling, R. W., Heymann, D. L., Teo, Y.-Y. & Garcia, P. J. Diagnostics for COVID-19: moving from pandemic response to control. Lancet 399, 757\u2013768 (2022).","journal-title":"Lancet"},{"key":"1323_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","volume":"384","author":"P Chen","year":"2021","unstructured":"Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 384, 229\u2013237 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR19","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR20","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","volume":"385","author":"M Dougan","year":"2021","unstructured":"Dougan, M. et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N. Engl. J. Med. 385, 1382\u20131392 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941\u20131950 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR22","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","volume":"383","author":"DA Berlin","year":"2020","unstructured":"Berlin, D. A., Gulick, R. M. & Martinez, F. J. Severe Covid-19. N. Engl. J. Med. 383, 2451\u20132460 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR23","doi-asserted-by":"publisher","first-page":"778434","DOI":"10.3389\/fmed.2021.778434","volume":"8","author":"AG Mainous","year":"2021","unstructured":"Mainous, A. G., Rooks, B. J., Wu, V. & Orlando, F. A. COVID-19 post-acute sequelae among adults: 12\u2009month mortality risk. Front. Med. (Lausanne) 8, 778434 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"1323_CR24","first-page":"838","volume":"2","author":"X He","year":"2021","unstructured":"He, X., Hong, W., Pan, X., Lu, G. & Wei, X. SARS-CoV-2 Omicron variant: characteristics and prevention. MedComm (2020) 2, 838\u2013845 (2021).","journal-title":"MedComm (2020)"},{"key":"1323_CR25","doi-asserted-by":"publisher","first-page":"e12998","DOI":"10.1111\/sji.12998","volume":"93","author":"AU Anka","year":"2021","unstructured":"Anka, A. U. et al. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. Scand. J. Immunol. 93, e12998 (2021).","journal-title":"Scand. J. Immunol."},{"key":"1323_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14348\/molcells.2021.0068","volume":"44","author":"SH Park","year":"2021","unstructured":"Park, S. H. An impaired inflammatory and innate immune response in COVID-19. Mol. Cells 44, 384\u2013391 (2021).","journal-title":"Mol. Cells"},{"key":"1323_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12931-021-01628-9","volume":"22","author":"T Mauad","year":"2021","unstructured":"Mauad, T. et al. Tracking the time course of pathological patterns of lung injury in severe COVID-19. Respir. Res. 22, 32 (2021).","journal-title":"Respir. Res."},{"key":"1323_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/cells10020386","volume":"10","author":"B Sun","year":"2021","unstructured":"Sun, B. et al. Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells 10, 386 (2021).","journal-title":"Cells"},{"key":"1323_CR29","doi-asserted-by":"publisher","first-page":"e148225","DOI":"10.1172\/JCI148225","volume":"131","author":"PJ Siska","year":"2021","unstructured":"Siska, P. J. et al. Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone. J. Clin. Invest. 131, e148225 (2021).","journal-title":"J. Clin. Invest."},{"key":"1323_CR30","doi-asserted-by":"publisher","first-page":"100033","DOI":"10.1016\/j.clinpr.2020.100033","volume":"7","author":"K Haigh","year":"2020","unstructured":"Haigh, K. et al. Hyperinflammation with COVID-19: the key to patient deterioration? Clin. Infect. Pr. 7, 100033 (2020).","journal-title":"Clin. Infect. Pr."},{"key":"1323_CR31","doi-asserted-by":"publisher","first-page":"12493","DOI":"10.18632\/aging.103579","volume":"12","author":"X Fang","year":"2020","unstructured":"Fang, X. et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY) 12, 12493\u201312503 (2020).","journal-title":"Aging (Albany NY)"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01323-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01323-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:03:59Z","timestamp":1675062239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01323-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01323-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HT, SSL, HWS, YY, and XCC are employees of Jiangsu Pacific Meinuoke Biopharmaceutical. All other authors declare no competing interests or financial relationships relevant to the submitted work. No form of payment was given to anyone to produce the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}